Mediclinic International FY18 Results Annoucement
PDF | 1.05 MB
Mediclinic announces its results for the year ended 31 March 2018 (the “reporting period” or “FY18”)
Danie Meintjes, CEO of Mediclinic, today commented:
“We were pleased with the Group’s performance this year given the various market and regulatory trends in each division. A key achievement was the strong second half performance in Abu Dhabi which, combined with the continued strong delivery in Dubai and the exciting expansion opportunities ahead, is laying the foundations for further growth across the Middle East division.
“The Southern Africa division delivered second half revenue growth and EBITDA margin improvement ahead of expectations for the year. In Switzerland, Hirslanden is adapting to the changing market and regulatory environment, absorbing the initial impact of these changes. Both divisions benefited from cost saving programmes and productivity initiatives implemented during the year.
“Current trading is in line with our expectations and the guidance for FY19 remains unchanged.
“As I approach my retirement as CEO of the Group, I would like to wish my successor, Dr Ronnie van der Merwe, and the team well. Having worked with Ronnie for many years, I firmly believe that he is the right person to lead Mediclinic through its next stage of growth and deliver on the many opportunities ahead. I look forward to continuing to support the Group as a non-executive director."